Nivalis Therapeutics, Inc. (ALPN)
(Delayed Data from NSDQ)
$6.24 USD
-0.08 (-1.27%)
Updated May 3, 2019 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ALPN]
Reports for Purchase
Showing records 41 - 60 ( 156 total )
Industry: Medical - Drugs
Q4 Financials; RUBY-3 and RUBY-4 Data On Track for YE:2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
2022 Results; Looking For Rubies by Year-End; Target Upped to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
3Q22 Results; ALPN-303 Takes the Lead as Key Value Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Q3 Financials; ALPN-303 Broad Development Plan on Track
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
ASH 2022 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
ALPN-303''s Luster Grows With Additional Data From RUBY-1
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Davoceticept Discontinued; Focus on ALPN-303 and Acazicolcept Going Forward
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Lights Out For NEON-1 and NEON-2; PT Reduced to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Biotechnology - Relevant Abstracts at SITC 2022
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
R&D Day Highlights ALPN-303''s and Davoceticept''s Recent Clinical Progress and Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
R&D Day Notes: ''303 Development to Expand Significantly
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Q2 Financials; ALPN-303 Ph 1 Data in 3Q:22, NEON-2 Data in 2H:22
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
Wedbush Healthcare Conference - That''s A Wrap; Key Takeaways
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Industry: Medical - Drugs
2Q22 Results; ALPN-303 Readies for Boost; Davoceticept Advances in NEON-1 and NEON-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
NEON-1 and NEON-2 Continue to Shine at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J